AtriCure Announces Upcoming Investor Conference Schedule
Canaccord Growth Conference 2014 Barrington Research Fall Investment
WEST CHESTER, Ohio -- July 29, 2014
AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device
provider, today announced that it will present at the Canaccord Genuity 34^th
Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday,
August 13, 2014. Management is scheduled to present at8:30 a.m. Eastern Time.
A live audio webcast and replay of the presentation will be available for 30
days following the presentation at http://wsw.com/webcast/canaccord14/atrc.
AtriCure management is also scheduled to participate in the Barrington
Research 7^th Annual Fall Investment Conference at the Four Seasons Hotel in
Chicago on September 4, 2014.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only surgical device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely sold device
worldwide that is indicated for the occlusion of the LAA.The company believes
cardiothoracic surgeons are adopting its ablation and LAA management devices
for the treatment of Afib and reduction of Afib related complications such as
stroke. Afib affects more than 5.5 million people worldwide.
Andy Wade, 513-755-4564
Vice President and Chief Financial Officer
Investor Relations Contact
Lynn Pieper, 415-202-5678
Press spacebar to pause and continue. Press esc to stop.